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Background: Frailty is a complex clinical syndrome associated with vulnerability to
adverse health outcomes. While frailty is thought to be common in chronic obstructive
pulmonary disease (COPD), the relationship between frailty and COPD-related outcomes
such as risk of acute exacerbations of COPD (AE-COPD) and hospitalizations is unclear.
Purpose: To examine the association between physical frailty and risk of acute exacerba-
tions, hospitalizations, and mortality in patients with COPD.
Methods: A longitudinal analysis of data from a cohort of 280 participants was performed.
Baseline frailty measures included exhaustion, weakness, low activity, slowness, and under-
nutrition. Outcome measures included AE-COPD, hospitalizations, and mortality over 2
years. Negative binomial regression and Cox proportional hazard modeling were used.
Results: Sixty-two percent of the study population met criteria for pre-frail and 23% were
frail. In adjusted analyses, the frailty syndrome was not associated with COPD exacerba-
tions. However, among the individual components of the frailty syndrome, weakness mea-
sured by handgrip strength was associated with increased risk of COPD exacerbations (IRR
1.46, 95% CI 1.09–1.97). The frailty phenotype was not associated with all-cause hospita-
lizations but was associated with increased risk of non-COPD-related hospitalizations.
Conclusion: This longitudinal cohort study shows that a high proportion of patients with
COPD are pre-frail or frail. The frailty phenotype was associated with an increased risk of
non-COPD hospitalizations but not with all-cause hospitalizations or COPD exacerbations.
Among the individual frailty components, low handgrip strength was associated with
increased risk of COPD exacerbations over a 2-year period. Measuring handgrip strength
may identify COPD patients who could benefit from programs to reduce COPD
exacerbations.
Keywords: chronic obstructive pulmonary disease, frailty, weakness, handgrip strength
Introduction
Chronic obstructive pulmonary disease (COPD) is a significant cause of morbidity and
remains the third leading cause of death in the United States.1 Acute exacerbations of
COPD (AE-COPD) frequently occur and place a significant utilization and cost burden
on the US healthcare system.2,3 Additionally, AE-COPD have been shown to accelerate
declines in lung function, health-related quality of life, and increase hospitalizations
and mortality.4–7 Identifying patients at high risk may help target interventions to
reduce AE-COPD.8–10 Risk factors for AE-COPD include age, sex, forced expiratory
volume (FEV1), and frequent prior exacerbations.
7–9,11,12
Frailty has been described as a state of decreased physiologic reserve causing
vulnerability to adverse events,13,14 and identifies individuals who are at risk for
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disability, adverse health outcomes, and increased all-
cause mortality.14–17 The frailty phenotype proposed by
Fried et al is widely accepted and is defined as the pre-
sence of three or more of the following measures: exhaus-
tion, weakness, slowness, low activity, and/or weight
loss,14,18 with pre-frailty defined as having 1–2 frailty
measures.19
COPD patients are twice as likely to be frail than those
without COPD, and a review of 27 studies found that an
estimated 19% were frail, with 56% meeting criteria for
pre-frailty.19,20 The prevalence of frailty varies by setting,
ranging from 9% to 28% in the majority of studies,
whereas pre-frailty prevalence varies from 48% to
64%.19 Few longitudinal studies have examined the asso-
ciation of frailty with COPD outcomes such as
exacerbations,20 and have used heterogenous definitions
of frailty.19 Most studies have used questionnaires to
assess frailty, with few using objectively measured muscle
strength or gait speed to assess frailty in people with
COPD. A longitudinal study using the Fried criteria
found that mortality among frail COPD patients was four
times higher than non-frail patients.20 Longitudinal studies
using questionnaires to measure frailty have found an
increased risk of re-admissions and mortality in
COPD.13,21 Also, among participants in the National
Emphysema Treatment Trial, frail COPD participants had
an increased risk of all-cause hospitalization and worse
quality of life.22
Frailty is defined as a syndrome; however, one of the
individual frailty components is muscle weakness mea-
sured by handgrip strength (HGS), which has been asso-
ciated with increased risk of acute COPD exacerbations in
a cross-sectional study.23 Limb muscle dysfunction is
common in COPD and contributes to poor clinical out-
comes including exercise tolerance and mortality.24,25
Importantly, limb muscle strength can be improved with
exercise training and is a modifiable risk factor for adverse
outcomes.
This study’s primary aim is to examine the relationship
between the frailty syndrome with the risk of COPD
exacerbations in a longitudinal outpatient cohort of
patients with COPD utilizing objectively measured muscle
strength and physical activity. We examined the impact of
grip strength and other individual components of frailty on
risk of adverse COPD outcomes. Additional aims are to
evaluate the associations between frailty and all-cause
hospitalizations, non-COPD hospitalizations, and
mortality.
Methods
Study Design
This study analyzed data collected as part of the COPD
Activity: Serotonin Transporter, Cytokine, and Depression
(CASCADE) study.26 Approvals were obtained by institu-
tional review boards, in compliance with the Declaration
of Helsinki, at the three clinical sites: University of
Washington, VA Puget Sound Health Care System, and
University of Texas Health Science Center-San Antonio.
All participants provided written informed consent.
Inclusion criteria included a diagnosis of COPD, post-
bronchodilator FEV1/FVC <0.70% and FEV1% predicted
<80%, age ≥40 years, current or past cigarette use (>10
pack-years), and stable disease in the past 4 weeks.
Exclusion criteria were: non-COPD lung disease (eg,
asthma, diffuse parenchymal lung disease), chronic inflam-
matory diseases, lung cancer or metastatic cancer, severe
chronic kidney disease, uncompensated heart failure,
advanced liver disease, HIV/AIDS, chronic antibiotic or
oral prednisone use, bipolar disease, psychotic disorders,
or dementia.
Measures
Disease Severity
Measures of disease severity included: forced expiratory
volume in 1 second, body mass index (BMI), home oxy-
gen use, Charlson co-morbidity index,27,28 COPD hospita-
lizations in the prior year, and dyspnea with Modified
Medical Research Council scale (mMRC).29 Individual
comorbidities were also examined including myocardial
infarction, angina, heart failure, peripheral vascular dis-
ease, stroke, hemiplegia, neurologic disease (multiple
sclerosis or Parkinson’s disease), pneumonia, ARDS,
drug abuse, peptic ulcer disease (history of endoscopy),
visual impairment, hearing impairment, degenerative disc
disease, diabetes, diabetes treatment (diet, oral hypoglyce-
mics or insulin), diabetes complications (eye, kidney),
post-traumatic stress disorder, chronic kidney disease,
rheumatoid arthritis, osteoarthritis, osteoporosis, cirrhosis,
leukemia, lymphoma, and non-metastatic cancer.
Frailty
Using baseline data, we adapted the 5 components of the
frailty phenotype model defined by Fried using the follow-
ing established measures:14 1) Exhaustion was defined as
a score of ≤55 on the vitality scale of the SF-36 quality of
life measure, an approach used in other studies of
frailty;30,31 2) Weakness was assessed using a Jamar
Yee et al Dovepress
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dynamometer (Fabrication Enterprises, White Plains,
NY).32 While standing, participants were instructed to
squeeze the grip handle as hard as they were able using
their dominant hand with a 90-degree flexion at the elbow.
The measurement was repeated 3 times and the best results
used. Low HGS was defined using cutoffs by Fried which
is commonly used and based on one cohort of older
participants.14 Because our cohort included younger parti-
cipants than in the Fried study, we also performed
a sensitivity analysis using a statistically based cutoff of
2 standard deviations below the gender-specific peak mean
from 12 large population studies by Dodd et al which
included participants <65 years;33 3) Participants wore
a StepWatch 3 Activity Monitor (OrthoCare Innovations,
Washington, DC)34,35 during waking hours for 7 consecu-
tive days. Low activity was defined as total daily step
count <2500,36 4) Slowness was defined as a cadence
<30 steps/minute,37 obtained using the StepWatch 3
Activity Monitor reflecting the average steps/minute dur-
ing the top 30 one-minute periods each day; and, 5)
Chronic undernutrition defined using the BMI cutoff of
≤21 as described in the BODE index.29
Other Covariates
Baseline demographic characteristics and smoking status
were obtained by questionnaire. Peak performance,
a measure of physical activity, was measured using the
StepWatch Activity Monitor and defined as the highest
number of steps per minute during the top 30 one-minute
periods each day.
Outcomes
Moderate-to-severe acute COPD exacerbations during the
2-year follow-up were defined as exacerbations treated with
prednisone and/or antibiotics, treated in the emergency
department or requiring hospitalization. AE-COPDs were
identified through standardized phone surveys every 3 to 4
months. All-cause mortality was reported to research coordi-
nators throughout the study duration.
Statistical Analysis
We compared unadjusted participant characteristics by the
frailty phenotype defined by Fried’s study: Non-frail (0
frailty measures), Pre-frail (1–2 frailty measures), and Frail
(≥3 frailty measures) using Wald test with robust standard
errors of linear regression models for continuous variables,
and Wald chi-square test for categorical variables. For sig-
nificant comparisons, we calculated p-values for each
pairwise comparison of baseline characteristic by frailty sta-
tus with adjustment for multiple testing with Bonferroni
correction. Next, we modeled the risk of moderate-to-
severe exacerbations, hospitalizations, and mortality over 2
years for each frailty measure. Regression models were
adjusted for the following baseline covariates: age, sex,
Charlson comorbidity index ≥1, supplemental home oxygen
use, COPD hospitalizations in the prior year, FEV1% pre-
dicted, and mMRC score. The logarithm of the total number
of days of follow-up was included in the model with the
coefficient constrained to 1 to measure time at risk. Due to
over-dispersion of AE-COPD and hospitalization data, nega-
tive binominal modeling was used producing incidence rates
ratios. Cox proportional hazards modeling was used for
survival analysis. To examine whether individual comorbid-
ities might confound the relationship between frailty and
COPD exacerbations, we examined the association between
comorbid conditions and both frailty and COPD exacerba-
tions. A sensitivity analysis was performed with variables
associated with frailty and COPD exacerbations at p <0.10
level to assess whether the coefficient for frailty changed by
>10%. Analyses were conducted using Stata 15.0 (StataCorp
LP, College Station, TX).
Results
Participant Characteristics and Frailty
Measures
This analysis included 280 participants with complete
measures of HGS, physical activity data, and longitudinal
follow-up out of 302 enrolled in the CASCADE study.
Overall, there was a high prevalence of frailty measures
(Figure 1).
Exhaustion (SF 36-vitality scale score < 55) was
present in 65.6% of participants, slowness (cadence <
30 steps/min) in 52.8%, weakness (low HGS) in 30.1%.
Nearly two-thirds of participants fell into the pre-frail
category with 1–2 frailty measures (62.4%).
Approximately a quarter had 3 or more frailty measures
(23.4%) consistent with the frailty phenotype. When
using the criteria by Dodd et al to define weakness
(low handgrip strength), there was a slightly larger pro-
portion of patients classified as having weakness (37.2%
vs 30.1%). The proportion of patients who were pre-frail
and frail were similar using the Dodd HGS criteria (non-
frail 13.1%, pre-frail 62.1%, frail 24.8%). The study
cohort was mainly white non-Hispanic (88%), male
(80%) with mean age of 68 years. Non-white participants
Dovepress Yee et al
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were more likely to be pre-frail or frail (p = 0.04).
Comparison of the baseline characteristics found that
frail participants were more likely to use home supple-
mental oxygen (p < 0.001; Table 1).
Frailty and Acute Exacerbations of COPD
The unadjusted rates of moderate-to-severe exacerbations
did not differ significantly by frailty phenotype class
(Table 2).
Results from adjusted negative binomial regression
models examining the association between frailty and
acute exacerbations are summarized in Table 3.
There was no association between the frailty phenotype
(≥3 criteria) and increased risk of moderate-to-severe AE-
COPD. Among the individual frailty components,
exhaustion was associated with higher risk of moderate-
to-severe AE-COPD (IRR 1.47, 95% CI 1.07–2.01) in
unadjusted models but not after adjustment for co-
variates (IRR 1.25, 95% CI 0.93–1.69). Only weakness,
measured by low HGS defined using Fried criteria, was
associated with increased risk of AE-COPD (IRR 1.46,
95% CI 1.09–1.97) in adjusted models. Sensitivity analysis
using low HGS as defined by Dodd also showed an asso-
ciation with increased risk of AE-COPD (IRR 1.40, 95%
CI 1.05–1.85). The frailty measures of slowness and
undernutrition were not associated with increased risk of
AE-COPD in unadjusted or adjusted models. Low physical
activity was associated with a decreased risk of AE-COPD
in adjusted models.
In sensitivity analyses, we examined whether indivi-
dual comorbidities were associated with frailty and COPD
exacerbations, and found that only neurologic disease
(multiple sclerosis and Parkinson’s disease) were asso-
ciated with both frailty and COPD exacerbations at
a p<0.10. Adding neurologic disease to the final model
did not change the results (data not shown).
Frailty and Hospitalizations
Those defined as frail (≥3 frailty measures) had an
increased risk of all-cause hospitalization in the unadjusted
analysis using the frailty measure of weakness as defined
by Fried et al (IRR 2.26, 95% CI 1.09–4.71), but failed to
have a significant association in adjusted analyses (IRR
1.96, 95% CI 0.92–4.19). In both unadjusted and adjusted
analyses, individual frailty measures of exhaustion, weak-
ness, slowness, low activity, and undernutrition were not
significantly associated with risk of all-cause hospitaliza-
tions (Table 3).
In an analysis restricted to non-COPD-related hospitali-
zations, participants with the frailty phenotype were at
increased risk of non-COPD-related hospitalizations (IRR
2.62, 95% CI 1.00–6.84, p = 0.05). Among the individual
frailty measures, slowness was significantly associated with
increased risk of non-COPD hospitalizations whereas there
was a non-significant increased risk of non-COPD hospitali-
zations with exhaustion, weakness and low activity.
In a sensitivity analysis using the Dodd et al criteria for
weakness based on low handgrip strength, similar results
were seen (Table 4).
Frailty and Mortality
There was a low number of deaths in our study population
with most deaths occurring in those who were frail (Table
Figure 1 Prevalence of frailty measures at baseline. (A) Prevalence of individual
frailty measures: Exhaustion (Short Form Health Survey 36 scale score <50);
Weakness (low handgrip strength); Slowness (Cadence <30 steps per minute);
Low activity (total daily steps <2500); Undernutrition (body mass index ≤21). (B)
Prevalence of frailty phenotypes: non-frail (0 frailty measures); pre-frail (1–2 frailty
measures); Frail (≥3 frailty measures).
Yee et al Dovepress
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2). In unadjusted analysis, there was an association
between weakness as defined by Dodd and increased risk
of mortality (HR 2.36, 95% CI 1.03–5.38). In all other
unadjusted and adjusted analysis, there was no significant
association between frailty measures and death (Table 5).
Discussion
In this prospective cohort study of COPD patients, the pre-
valence of pre-frailty and frailty was high. The frailty phe-
notype was associated with an increased risk of non-COPD
hospitalizations, but not with the risk of moderate-to-severe
Table 1 Participant Characteristics (N=280)
Not Frail n=40 Pre-Frail n=176 Frail n=64 P-value*
Age, yr, mean (SD) 69.4 (8.0) 66.9 (8.4) 68.6 (9.2) 0.14
Sex, female (%) 10 (25.0) 34 (19.3) 12 (18.2) 0.67
Race, non-White (%) 0 23 (13.1) 10 (15.2) 0.04b
BMI
Mean (SD) 28.5 (3.9) 28.0 (5.9) 28.0 (7.9) 0.82
Low BMI (≤21) 0 12 (6.8) 17 (25.8) <0.001a,b,c
Current smoker (%) 8 (20.0) 47 (26.7) 21 (31.8) 0.41
COPD Disease severity
FEV1% predicted mean (SD) 49.5 (15.1) 46.9 (15.4) 36.9 (14.5) <0.001
b,c
GOLD severity category 0.002b,c
Moderate (50–80%) 20 (50.0) 78 (44.3) 14 (21.2)
Severe (30–49%) 14 (35.0) 71 (40.3) 30 (45.5)
Very severe (<30%) 6 (15.0) 27 (15.3) 22 (33.3)
mMRC, mean (SD) 1.3 (0.8) 1.9 (1.1) 2.6 (1.0) <0.001a,b,c
Home supplemental oxygen (%) 9 (22.5) 51 (29.0) 36 (54.6) <0.001b,c
≥ 1 COPD hospitalization prior yr (%) 14 (35) 75 (43) 35 (52) 0.23
Comorbidity
Charlson Comorbidity Index, ≥1 (%) 18 (45.0) 85 (48.3) 35 (53.0) 0.70
Non-metastatic cancer** 7 (17.5) 19 (10.8) 9 (13.6) 0.48
Neurologic disease# 3(7.5) 3 (1.7) 1 (1.5) 0.09
Physical Function
6MWT, mean (SD), feet 1301 (277) 1136 (343) 844(377) <0.001a,b,c
Physical Activity Data
Total Daily Steps, mean (SD) 7943 (2978) 6675 (3139) 3030 (1981) <0.001b,c
Low physical activity (<2500 steps/day) 0 3 (1.7) 36 (54.6) <0.001a,b,c
Slowness (cadence <30 steps/minute) 0 85 (48.3) 64 (97.0) <0.001a,b,c
Peak Performance, mean (SD)## 36.1 (5.0) 31.6 (7.5) 20.8 (6.8) <0.001a,b,c
SF-36 Vitality Score
Mean Vitality Score (SD) 60.9 (5.4) 46.2 (11.7) 39.2 (9.9) <0.001a,b,c
Low Vitality Score (≤55) 0 124 (70.5) 62 (93.9) <0.001a,b,c
Handgrip strength, Kg
Mean Handgrip strength (SD) 35.2 (8.3) 33.9 (9.6) 26.2 (7.8) <0.001b,c
Low handgrip strength by Fried criteria 0 38 (21.6) 48 (72.7) <0.001a,b,c
Low handgrip strength by Dodd criteria 3 (7.5) 52 (29.6) 50 (75.8) <0.001a,b,c
Notes: *P-value for Wald test with robust standard errors of linear regression models for continuous variables, and Wald chi-square test for categorical variables. **Non-
skin cancer, no lymphoma or leukemia. #Multiple sclerosis or Parkinson’s. ##Peak performance is defined as the top steps/minute during the top 30 one-minute periods
each day. ap<0.0167 comparing not frail and pre-frail participants. bp<0.0167 comparing not frail and frail participants. cp<0.0167 comparing pre-frail and frail participants.
Abbreviations: SD, standard deviation; BMI, body mass index; mMRC, Modified Medical Research Council Dyspnea Scale; SF-36, Short Form Health Survey 36.
Dovepress Yee et al
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exacerbations in adjusted analyses. Of the five standard mea-
sures of frailty, only handgrip strength was independently
associated with increased risk of moderate-to-severe AE-
COPD.
Our findings add to the existing evidence that pre-
frailty and frailty are common among persons with
COPD. The prevalence of the frailty phenotype using the
criteria of Fried et al in this outpatient cohort of COPD
Table 2 Mean Annual Exacerbation, Hospitalization Rates and Mortality by Frailty Category
Outcome Not Frail n=40 Pre-Frail n=176 Frail n=64 P-value*
Moderate-to-severe exacerbations per year, mean (SD) 0.59 (0.70) 0.75 (0.89) 0.87 (1.16) 0.27
All-cause hospitalizations per year, mean (SD) 0.20 (0.41) 0.34 (0.65) 0.49 (0.68) 0.02b
Non-COPD hospitalizations per year, mean (SD) 0.10 (0.23) 0.17 (0.41) 0.22 (0.37) 0.12
Mortality, n (%) 3 (7.5) 8 (4.6) 10 (15.2) 0.02c
Notes: *P-value for Wald test with robust standard errors of linear regression models for continuous outcome variables and Wald chi-square test for mortality frequency.
bp<0.0167 comparing not frail and frail participants. cp<0.0167 comparing pre-frail and frail participants.
Table 3 Associations Between Frailty Measures and Acute COPD Exacerbations and All-Cause Hospitalizations Using Handgrip
Strength Based on Fried et al Criteria
Frailty Measures* Moderate-Severe COPD
Exacerbations
All-Cause
Hospitalizations
Non-COPD
Hospitalizations
Adj. IRR (CI)** p-value Adj. IRR (CI)** p-value Adj. IRR (CI)** p-value
Number of frailty measures
Non-frail (0) ref ref ref
Pre-frail (1–2) 1.13 (0.74–1.72) 0.57 1.36 (0.70–2.64) 0.36 1.58 (0.68–3.70) 0.29
Frail (≥3) 1.14 (0.69–1.89) 0.62 1.96 (0.92–4.19) 0.08 2.62 (1.00–6.84) 0.05
Individual frailty components
Exhaustion (SF 36-vitality score <55) 1.25 (0.93–1.69) 0.14 1.49 (0.95–2.33) 0.09 1.51 (0.86–2.66) 0.15
Weakness (Low HGS based per Fried) 1.46 (1.09–1.97) 0.01 1.27 (0.81–2.01) 0.30 1.23 (0.70–2.18) 0.47
Slowness (Cadence <30 steps/min) 0.86 (0.64–1.16) 0.32 1.14 (0.74–1.76) 0.55 1.96 (1.13–3.38) 0.02
Low activity (Total daily steps <2500) 0.55 (0.35–0.88) 0.01 1.03 (0.56–1.91) 0.93 1.33 (0.61–2.90) 0.48
Undernutrition (BMI ≤21) 0.95 (0.61–1.47) 0.80 0.93 (0.47–1.85) 0.84 0.83 (0.34–2.04) 0.69
Notes: *Each frailty measure represents an independent model. **Adjusted for Age, Sex, Charlson comorbidity index ≥ 1, FEV1, nMRC, Home O2, Prior COPD
hospitalizations in the past year.
Abbreviations: IRR, incidence rate ratio; CI, confidence interval; SF-36, Short Form Health Survey 36; HGS, handgrip strength; BMI, body mass index.
Table 4 Sensitivity Analysis: Associations Between Frailty Measures and Acute COPD Exacerbations and All-Cause Hospitalizations
Using Handgrip Strength Based on Dodd et al Criteria
Frailty Measures* Mod-Severe COPD
Exacerbations
All-Cause
Hospitalizations
Non-COPD
Hospitalizations
Adj. IRR (CI)** p-value Adj. IRR (CI)** p-value Adj. IRR (CI)** p-value
Number of frailty measures
Non-frail (0) Ref Ref Ref
Pre-frail (1–2) 1.13 (0.73–1.75) 0.59 1.16 (0.59–2.27) 0.67 1.30 (0.55–3.08) 0.54
Frail (≥3) 1.12 (0.67–1.87) 0.65 1.83 (0.86–3.88) 0.12 2.62 (1.02–6.74) 0.05
Weakness (Low HGS based
per Fried)
1.40 (1.05–1.85) 0.02 1.27 (0.83–1.96) 0.27 1.47 (0.87–2.49) 0.15
Notes: *Each frailty measure represents an independent model. **Adjusted for Age, Sex, Charlson comorbidity index ≥ 1, FEV1, mMRC, Home O2, Prior COPD
hospitalizations in the past year.
Abbreviations: IRR, incidence rate ratio, CI, confidence interval HGS, handgrip strength.
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patients was similar to the pooled prevalence described in
a systematic review by Marengoni (23% vs 19%,
respectively).19 Similarly, the prevalence of pre-frailty in
this study was 64%, compared to 56% described by
Marengoni et al.19
Like other studies we found that frailty is associated
with non-COPD hospitalizations, however, the frailty syn-
drome as a whole was not associated with the key COPD
outcome of exacerbations. When the individual compo-
nents of the frailty syndrome were examined separately,
however, handgrip strength was predictive of COPD
exacerbations. To the best of our knowledge, this is the
first study that describes an association between low HGS
and increased risk of AE-COPD in a prospective analysis,
and the results are consistent with a cross-sectional study
that found that HGS was associated with risk of COPD
exacerbations in the past year.23,38 HGS is also associated
with quality of life measured with the EuroQOL EQ-5D in
COPD,39 and another measure of limb muscle strength,
quadriceps strength, predicted mortality in COPD.25 Limb
muscle dysfunction is common in COPD, and is related to
poor exercise tolerance.24 The exact mechanism in which
low HGS contributes to increased risk of AE-COPD has
not been well understood, however. The relationship
between HGS and exacerbations was similar whether we
used the same cut-offs for low HGS from Fried’s original
study, or using the reference range by Dodd et al that
defined low HGS as 2 standard deviations below the pre-
dicted peak handgrip strength as an adult.14,33
Frailty is a broader syndrome than low handgrip
strength and is characterized by a physiologic state of
decreased reserve causing vulnerability to adverse
events.40,42 Overall the relationship between frailty and
COPD outcomes is unclear.19,42 We used Fried’s frame-
work to define frailty based on the presence of ≥3 out of 5
frailty measures.14 Since we did not have identical mea-
sures used to define the Fried criteria, we used externally
validated criteria. We defined frailty measures of slowness
and low activity with objectively measured data obtained
through a validated accelerometer, undernutrition by base-
line BMI, and exhaustion by the SF 36-vitality scale score.
Interestingly, we found that except for handgrip
strength, the other 4 measures of physical frailty were
not associated with a significantly increased risk of AE-
COPD. Exhaustion showed a trend towards increased risk
of exacerbations, but slowness, low activity and under-
nutrition were not associated with exacerbations. Low
physical activity, defined as total daily steps <2500,36
was associated with a decreased exacerbation risk (IRR
0.55, 95% CI 0.35–0.88), but there was no association
between low physical activity and risk of non-COPD hos-
pitalizations. This result was unexpected as prior studies
have shown that decreasing step count is associated with
an increased risk of acute exacerbations and COPD
hospitalizations.43–45 The reason why low physical activity
might reduce exacerbation risk is unclear, although
patients with low step counts may theoretically be
limiting potential environmental exposures triggering
exacerbations.
We had few participants with undernutrition (10%) and
were not able to assess weight loss prior to baseline visit,
limiting the utility of this frailty measure. Therefore, in
Table 5 Associations Between Frailty Measures and Mortality
Frailty Measures* Adjusted HR (CI)** P-value
Number of frailty measures
0 Ref
1–2 0.58 (0.15–2.29) 0.43
≥3 1.47 (0.34–6.38) 0.61
Individual frailty components
Exhaustion (SF 36-vitality scale score <55) 0.83 (0.34–1.99) 0.67
Weakness (Low HGS per Fried) 1.31 (0.33–1.96) 0.30
Weakness (Low HGS per Dodd) 1.49 (0.61–3.61) 0.38
Slowness (Cadence <30 steps/min) 1.93 (0.67–5.53) 0.22
Low activity (Total daily steps <2500) 1.16 (0.36–3.76) 0.81
Undernutrition (Low weight BMI ≤21) 1.87 (0.58–6.01) 0.29
Notes: *Each frailty measure represents an independent model. **Adjusted for Age, Sex, Charlson comorbidity index ≥ 1, FEV1, MMRC, Home O2, Prior
COPD hospitalizations in the past year.
Abbreviations: HR, hazard ratio; SF-36, Short Form Health Survey 36; HGS, handgrip strength; BMI, body mass index.
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COPD, physical measures of frailty such as slowness, low
activity, and undernutrition appear to be less predictive of
AE-COPD than weakness or exhaustion. The participants
in this study had moderate-to-severe COPD and therefore
it is possible that some of the frailty components such as
slowness and low activity are already captured in the
COPD severity measures of FEV1, dyspnea (mMRC)
and home oxygen use. We found that frailty was asso-
ciated with increased risk of non-COPD-related hospitali-
zations. This suggests that the frailty phenotype is still an
important risk factor for non-COPD-related
hospitalizations.
Although the frailty phenotype was associated with
increased risk of mortality, this were not statistically sig-
nificant. We suspect this was largely driven by a lack of
statistical power given the low number of deaths (21
deaths) over the two-year course of the study. This is
supported by the fact that two factors that commonly
associated with mortality in COPD (low BMI29 and
weakness46) had increased point estimates for morality
but were not statistically significant.
Our finding that HGS is the main frailty measure pre-
dictive of AE-COPD supports other studies that have sug-
gested that HGS alone may be a useful marker of frailty and
those with decreased physiologic reserve.47,48 Assessing
weakness by measuring handgrip strength can be easily
done in clinical practice for COPD patients and could pro-
vide important prognostic information and identify patients
who may benefit from targeted interventions.18,19 Prior stu-
dies have shown reversibility in frailty and sarcopenia status
with pulmonary rehabilitation.19,40,41,49 More detailed long-
itudinal studies on frailty, weakness, and COPD-related out-
comes are warranted in addition to further study on the
potential impact of pulmonary rehabilitation on COPD out-
comes in frail patients.
Several limitations are worth noting. The majority of our
sample were men and frailty is more common in older
women.50 Additionally, due to the primary aim of the main
study, participants were excluded if they were chronically
using oral corticosteroids or had chronic inflammatory states
other than COPD. Although these exclusion criteria reduced
the confounding because of steroids or other inflammatory
states on the relationship between frailty andCOPDoutcomes,
they may limit the generalizability of our findings and may
have selected for a heathier baseline study population. Another
potential limitation is the use of frailty measure definitions that
did not exactly match the original Fried definitions. However,
similar to others,22 we were careful to use externally
developed criteria to represent the measures of exhaustion,
slowness, low physical activity, and undernutrition/weight
loss.
The use of accelerometer data from a 7-day period to
define slowness and low physical activity may be biased by
the Hawthorne effect, in which participants behave differ-
ently initially due to being observed but over time return to
their usual physical activity not captured by the acceler-
ometer. In the final model to predict non-COPD hospitaliza-
tions, we were not able to adjust for prior non-COPD
hospitalizations which may have influenced the results. As
previously discussed, the low number of deaths over the
study duration likely resulted in an underpowered analysis
for evaluation between frailty and mortality. Finally, exacer-
bation and hospitalization data were obtained through reg-
ular surveys, but ultimately reliant on patient self-report.
Conclusion
The results of this longitudinal cohort study show a high
proportion of patients with COPD are either frail or pre-
frailty of frailty, and that the individual frailty measure of
weakness, as defined by low handgrip strength, was signifi-
cantly associated with increased risk of moderate-to-severe
acute exacerbations of COPD. The frailty phenotype was not
associated with COPD exacerbations but was associated with
an increased risk of non-COPD-related hospitalizations.
Evaluating weakness as measured by low handgrip strength
in patients with COPD identifies a high-risk population that
could potentially benefit from targeted interventions to pre-
vent exacerbations and for interventions that can improve
muscle weakness in COPD such as pulmonary rehabilitation.
Future studies should examine whether interventions for
frailty and weakness may reduce adverse outcomes in COPD.
Abbreviations
AE-COPD, acute exacerbations of chronic obstructive pul-
monary disease; BMI, body mass index; CASCADE Study,
COPD Activity: Serotonin Transporter, Cytokine, and
Depression Study; CI, confidence interval; COPD, chronic
obstructive pulmonary disease; FEV1, forced expiratory
volume; FVC, forced vital capacity; HGS, handgrip strength;
IRR, incident rate ratio; SD, standard deviation.
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